摘要
目的 :比较治疗帕金森病的两种方法 ,评价帕金森病治疗方法的效果。方法 :采用前瞻性队列试验研究的方法 ,根据病人应用的不同药物把病人分为左旋多巴治疗组 (A组 )、左旋多巴 +多巴胺受体兴奋性治疗组织 (B组 )。分别评价两组病人的治疗效果、生活质量、治疗成本。治疗效果评价采用统一的帕金森病评分量表 (UPDRS) ;生活质量采用数字法评价 ;治疗成本分为直接成本和间接成本。根据公式 :成本效果比 =治疗总成本 /治疗效果 (C/E)。结果 :共追踪调查 3 0 1例帕金森病人 ,A组为 1 47人 ,B组为 1 5 4人。A组的C/E为2 47.3 6;B组的C/E为 1 90 .81。B组较A组增加的C/E值为 3 1 7.84。药物成本与成本效果比的相关性最大 ,RR值为 1 7。病情严重程度的RR值为 1 4。间接成本的RR值为 1 3。结论 :治疗药物成本在总治疗成本中占的比例最大 ,应用多巴胺受体兴奋剂治疗帕金森病具有比较高的成本效果比 。
Objectives: To measure cost effectiveness of different PD’s pharmacotherapy, the factors that affect cost effectiveness and two PD’s treatment were discussed. Methods: The total 301 PD patients were divided into two groups according to different pharmacotherapy. PD patients’ curative effects, quality of life (QOL) and costs were respectively evaluated. The effectiveness was evaluated with unified parkinson’s disease rating scale (UPDRS). The QOL were measured with numeric method (0=death; 100=best possible health). Analyzed costs were divided into direct cost and indirect cost. The Cost effectiveness ratio was calculated with the formula C/E. Results: There were 147 cases in group A and 154 cases in group B. The cost effectiveness ratios of group A and group B were 247.36 and 190.81 in sequence. The incremental C/E ratio was 317.84. The costs of medicine were the most majority in the total costs and the most relative with cost effectiveness ratios, RR value is 17. The patient’s conditions and indirect costs were mostly related to the cost effectiveness ratio. Conclusions: The costs of medicine occupied the highest ratios in the total costs. The cost effectiveness ratio of applying Dopamine agonists was obvious. The costs of medicine were the most relative to the cost effectiveness ratio for PD’s pharmacotherapy.
出处
《四川生理科学杂志》
2004年第3期108-111,共4页
Sichuan Journal of Physiological Sciences
